

Act of 1930, as amended, 19 U.S.C. 1337, and in section 210.10 of the Commission's Rules of Practice and Procedure, 19 CFR 210.10 (2020).

*Scope of Investigation:* Having considered the complaint, the U.S. International Trade Commission, on September 1, 2020, ordered that—

(1) Pursuant to subsection (b) of section 337 of the Tariff Act of 1930, as amended, an investigation be instituted to determine whether there is a violation of subsection (a)(1)(B) of section 337 in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain products identified in paragraph (2) by reason of infringement of one or more of claims 1, 3, 6, 7, 12, 21–24, 29, 30, and 33–38 of the '985 patent and claim 1 of the '705 patent; and whether an industry in the United States exists as required by subsection (a)(2) of section 337;

(2) Pursuant to section 210.10(b)(1) of the Commission's Rules of Practice and Procedure, 19 CFR 210.10(b)(1), the plain language description of the accused products or category of accused products, which defines the scope of the investigation, is “variable speed wind turbine generators having low and zero voltage ride through capability and components thereof, namely generators, power converters, uninterruptible power supplies, turbine controllers, blade pitch control systems, and converter controllers”;

(3) For the purpose of the investigation so instituted, the following are hereby named as parties upon which this notice of investigation shall be served:

(a) The complainant is:

General Electric Company, 5 Necco Street, Boston, MA 02210

(b) The respondents are the following entities alleged to be in violation of section 337, and are the parties upon which the complaint is to be served:

Siemens Gamesa Renewable Energy Inc., 3500 Quadrangle Boulevard, Orlando, FL 32817

Siemens Gamesa Renewable Energy A/S, Borupvej 16, 7330 Brande, Denmark

Gamesa Electric, S.A.U., Parque Tecnológico de Bizkaia, Building 206, 48170 Zamudio, BI, Spain

(4) For the investigation so instituted, the Chief Administrative Law Judge, U.S. International Trade Commission, shall designate the presiding Administrative Law Judge.

The Office of Unfair Import Investigations will not participate as a party in this investigation.

Responses to the complaint and the notice of investigation must be submitted by the named respondents in accordance with section 210.13 of the Commission's Rules of Practice and Procedure, 19 CFR 210.13. Pursuant to 19 CFR 201.16(e) and 210.13(a), as amended in 85 FR 15,798 (Mar. 19, 2020), such responses will be considered by the Commission if received not later than 20 days after the date of service by the complainant of the complaint and the notice of investigation. Extensions of time for submitting responses to the complaint and the notice of investigation will not be granted unless good cause therefor is shown.

Failure of a respondent to file a timely response to each allegation in the complaint and in this notice may be deemed to constitute a waiver of the right to appear and contest the allegations of the complaint and this notice, and to authorize the administrative law judge and the Commission, without further notice to the respondent, to find the facts to be as alleged in the complaint and this notice and to enter an initial determination and a final determination containing such findings, and may result in the issuance of an exclusion order or a cease and desist order or both directed against the respondent.

By order of the Commission.

Issued: September 1, 2020.

**Lisa Barton,**

*Secretary to the Commission.*

[FR Doc. 2020–19747 Filed 9–4–20; 8:45 am]

**BILLING CODE 7020–02–P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA–710]

#### Importer of Controlled Substances Application: Cambridge Isotope Laboratories

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Cambridge Isotope Laboratories has applied to be registered as an importer of basic class(es) of controlled substances. Refer to Supplemental Information listed below for further drugs information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before October 8, 2020. Such persons

may also file a written request for a hearing on the application on or before October 8, 2020.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA **Federal Register** Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA **Federal Register** Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on July 23, 2020, Cambridge Isotope Laboratories, 50 Frontage Road, Andover, Massachusetts 01810, applied to be registered as an importer of the following basic class(es) of controlled substances:

Controlled substance	Drug code	Schedule
Gamma Hydroxybutyric Acid.	2010	I
Tetrahydrocannabinols ..	7370	I
Morphine .....	9300	II

The company plans to import the listed controlled substances for analytical research, testing and clinical trials. No other activity for these drug codes is authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

**William T. McDermott,**

*Assistant Administrator.*

[FR Doc. 2020–19806 Filed 9–4–20; 8:45 am]

**BILLING CODE 4410–09–P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA–708]

#### Bulk Manufacturer of Controlled Substances Application: Cayman Chemical Company

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Cayman Chemical Company has applied to be registered as a bulk manufacturer of basic class(es) controlled substances. Refer to Supplemental Information listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before November 9, 2020. Such persons may also file a written request

for a hearing on the application on or before November 9, 2020.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA **Federal Register** Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn:

Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA **Federal Register** Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on July 17, 2020, Cayman Chemical Company, 1180 East Ellsworth Road, Ann Arbor, Michigan 48108-2419, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substances:

Controlled substance	Drug code	Schedule
3-Fluoro-N-methylcathinone (3-FMC); 1-(3-Fluorophenyl)-2-(Methylamino)Propan-1-one	1233	
Cathinone	1235	
Methcathinone	1237	
4-Fluoro-N-methylcathinone (4-FMC); Flephedrone; 1-(4-Fluorophenyl)-2-(Methylamino)Propan-1-one	1238	
Pentedrone ( $\alpha$ -methylaminovalerophenone), its optical, positional and geometric isomers, salts and salts of isomers	1246	
Mephedrone (4-Methyl-N-methylcathinone)	1248	
4-Methyl-N-ethylcathinone (4-MEC)	1249	
Naphyrone, its optical, positional and geometric isomers, salts and salts of isomers	1258	
N-Ethylamphetamine	1475	
N,N-Dimethylamphetamine	1480	
Fenethylamine	1503	
Aminorex	1585	
4-Methylaminorex (cis isomer)	1590	
Gamma Hydroxybutyric Acid	2010	
Methaqualone	2565	
Mecloqualone	2572	
JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole)	6250	
SR-18 (Also known as RCS-8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole)	7008	
ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide)	7010	
5-Flouro-UR-144 and XLR11 [1-(5-Fluoro-pentyl)1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone	7011	
AB-FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide)	7012	
FUB-144	7014	
JWH-019 (1-Hexyl-3-(1-naphthoyl)indole)	7019	
MDMB-FUBINACA (Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate)	7020	
2-(1-(4-fluorobenzyl)-1Hindazole-3-carboxamido)-3-methylbutanoate	7021	
AB-PINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide)	7023	
THJ-2201 [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone	7024	
5F-AB-PINACA	7025	
AB-CHMINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide)	7031	
MAB-CHMINACA (N-(1-amino-3,3dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide)	7032	
5F-AMB (Methyl 2-(1-(5-fluoropentyl)-1H-indazola-3-carboxamido)-3-methylbutanoate)	7033	
5F-ADB; 5F-MDMB-PINACA (Methyl 2-(1-(5fluoropentyl)-1H-indazole-3-carboxamido)-3,3dimethylbutanoate)	7034	
ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide)	7035	
5F-EDMB-PINACA	7036	
5F-MDMB-PICA)	7041	
MDMB-CHMICA, MMB-CHMINACA (Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate)-	7042	
MMB-CHMICA	7044	
FUB-AKB48;FUB-APINACA; AKB48 N-(4-Fluorobenzyl)	7047	
APINACA and AKB48 N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide	7048	
5F-APINACA, 5F-AKB48 (N-(adamantan-1-yl)-1-(5fluoropentyl)-1H-indazole-3-carboxamide)	7049	
JWH-081 (1-Pentyl-3-(1-(4-methoxynaphthoyl) indole)	7081	
5F-CUMYL-PINACA;SGT-25	7083	
5F-CUMYL-P7AICA	7085	
4-CN-CUMYL-BUTINACA	7089	
SR-19 (Also known as RCS-4) (1-Pentyl-3-[(4-methoxy)-benzoyl] indole	7104	
JWH-018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole)	7118	
JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole)	7122	
UR-144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone	7144	
JWH-073 (1-Butyl-3-(1-naphthoyl)indole)	7173	
JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole)	7200	
AM2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl) indole)	7201	
JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl) indole)	7203	
NM2201	7221	
PB-22 (Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate)	7222	
5F-PB-22 (Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate)	7225	
4-Methyl-Alpha-Ethylaminopentiophenone	7245	

Controlled substance	Drug code	Schedule
N-Ethylhexedrone, its optical, positional and geometric isomers, salts and salts of isomers	7246	I
Alpha-ethyltryptamine	7249	I
Ibogaine	7260	I
CP-47,497 (5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol])	7297	I
CP-47,497 C8 Homologue (5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol])	7298	I
Lysergic acid diethylamide	7315	I
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7)	7348	I
Marihuana	7360	I
Tetrahydrocannabinols	7370	I
Mescaline	7381	I
2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine (2C-T-2)	7385	I
3,4,5-Trimethoxyamphetamine	7390	I
4-Bromo-2,5-dimethoxyamphetamine	7391	I
4-Bromo-2,5-dimethoxyphenethylamine	7392	I
4-Methyl-2,5-dimethoxyamphetamine	7395	I
2,5-Dimethoxyamphetamine	7396	I
JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl) indole)	7398	I
2,5-Dimethoxy-4-ethylamphetamine	7399	I
3,4-Methylenedioxyamphetamine	7400	I
5-Methoxy-3,4-methylenedioxyamphetamine	7401	I
N-Hydroxy-3,4-methylenedioxyamphetamine	7402	I
3,4-Methylenedioxy-N-ethylamphetamine	7404	I
3,4-Methylenedioxymethamphetamine	7405	I
4-Methoxyamphetamine	7411	I
5-Methoxy-N,N-dimethyltryptamine	7431	I
Alpha-methyltryptamine	7432	I
Bufotenine	7433	I
Diethyltryptamine	7434	I
Dimethyltryptamine	7435	I
Psilocybin	7437	I
Psilocyn	7438	I
5-Methoxy-N,N-diisopropyltryptamine	7439	I
4-CHLORO-ALPHA-Pyrrolidinovalerophenone, its optical, positional and geometric isomers, salts and salts of isomers	7443	I
4-METHYL-ALPHA-Pyrrolidinohexiophenone, its optical, positional and geometric isomers, salts and salts of isomers	7446	I
N-Ethyl-1-phenylcyclohexylamine	7455	I
1-(1-Phenylcyclohexyl)pyrrolidine	7458	I
1-[1-(2-Thienyl)cyclohexyl]piperidine	7470	I
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine	7473	I
N-Benzylpiperazine	7493	I
4-Methyl-Alpha-pyrrolidinopropiophenone, its optical, positional and geometric isomers, salts and salts of isomers	7498	I
2-(2,5-Dimethoxy-4-methylphenyl) ethanamine (2C-D)	7508	I
2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine (2C-E)	7509	I
2-(2,5-Dimethoxyphenyl) ethanamine (2C-H)	7517	I
2-(4-iodo-2,5-dimethoxyphenyl) ethanamine (2C-I)	7518	I
2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine (2C-C)	7519	I
2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine (2C-N)	7521	I
2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine (2C-P)	7524	I
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl] ethanamine (2C-T-4)	7532	I
MDPV (3,4-Methylenedioxyprovalerone)	7535	I
2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25B-NBOMe)	7536	I
2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe)	7537	I
2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I-NBOMe)	7538	I
Methylone (3,4-Methylenedioxy-N-methylcathinone)	7540	I
Butylone, its optical, positional and geometric isomers, salts and salts of isomers	7541	I
Pentylone, its optical, positional and geometric isomers, salts and salts of isomers	7542	I
N-Ethylpentylone, or Ephylone	7543	I
ALPHA-Pyrrolidinohexanophenone	7544	I
alpha-pyrrolidinopentiophenone ( $\alpha$ -PVP), its optical, positional and geometric isomers, salts and salts of isomers	7545	I
alpha-pyrrolidinobutiophenone ( $\alpha$ -PBP), its optical, positional and geometric isomers, salts and salts of isomers	7546	I
Ethylone	7547	I
ALPHA-Pyrrolidinoheptaphenone, its optical, positional and geometric isomers, salts and salts of isomers	7548	I
AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl) indole)	7694	I
Acetyldihydrocodeine	9051	I
Benzylmorphine	9052	I
Codeine-N-oxide	9053	I
Desomorphine	9055	I
Etorphine (except HCl)	9056	I
Codeine methylbromide	9070	I
Dihydromorphine	9145	I
Heroin	9200	I
Morphine-N-oxide	9307	I
Normorphine	9313	I
U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide)	9547	I

Controlled substance	Drug code	Schedule
AH-7921 .....	9551	I
MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine) .....	9560	I
Etonitazene .....	9624	I
Ketobemidone .....	9628	I
Tilidine .....	9750	I
Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide) .....	9811	I
Para-Fluorofentanyl .....	9812	I
3-Methylfentanyl .....	9813	I
Alpha-methylfentanyl .....	9814	I
Acetyl-alpha-methylfentanyl .....	9815	I
N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide .....	9816	I
Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) .....	9821	I
Butyryl Fentanyl .....	9822	I
Para-fluorobutyryl fentanyl .....	9823	I
4-Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide) .....	9824	I
2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide .....	9825	I
Para-chloroisobutyryl fentanyl .....	9826	I
Isobutyryl fentanyl .....	9827	I
Beta-hydroxyfentanyl .....	9830	I
Beta-hydroxy-3-methylfentanyl .....	9831	I
Alpha-methylthiofentanyl .....	9832	I
3-Methylthiofentanyl .....	9833	I
Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide) .....	9834	I
Thiofentanyl .....	9835	I
Beta-hydroxythiofentanyl .....	9836	I
Para-methoxybutyryl fentanyl .....	9837	I
Ocfentanil .....	9838	I
Valeryl fentanyl .....	9840	I
N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide .....	9843	I
Cyclopropyl Fentanyl .....	9845	I
Cyclopentyl fentanyl .....	9847	I
Fentanyl related-compounds as defined in 21 CFR 1308.11(h) .....	9850	I
Amphetamine .....	1100	II
Methamphetamine .....	1105	II
Lisdexamfetamine .....	1205	II
Phenmetrazine .....	1631	II
Methylphenidate .....	1724	II
Amobarbital .....	2125	II
Pentobarbital .....	2270	II
Secobarbital .....	2315	II
Glutethimide .....	2550	II
1-Phenylcyclohexylamine .....	7460	II
Phencyclidine .....	7471	II
4-Anilino-N-phenethyl-4-piperidine (ANPP) .....	8333	II
Norfentanyl .....	8366	II
Phenylacetone .....	8501	II
1-Piperidinocyclohexanecarbonitrile .....	8603	II
Cocaine .....	9041	II
Codeine .....	9050	II
Etorphine HCl .....	9059	II
Dihydrocodeine .....	9120	II
Oxycodone .....	9143	II
Hydromorphone .....	9150	II
Ecgonine .....	9180	II
Ethylmorphine .....	9190	II
Hydrocodone .....	9193	II
Levomethorphan .....	9210	II
Levorphanol .....	9220	II
Isomethadone .....	9226	II
Meperidine .....	9230	II
Meperidine intermediate-B .....	9233	II
Methadone .....	9250	II
Dextropropoxyphene, bulk (non-dosage forms) .....	9273	II
Morphine .....	9300	II
Thebaine .....	9333	II
Oxymorphone .....	9652	II
Thiafentanil .....	9729	II
Alfentanil .....	9737	II
Remifentanil .....	9739	II
Sufentanil .....	9740	II
Carfentanil .....	9743	II
Tapentadol .....	9780	II
Fentanyl .....	9801	II

The company plans to bulk manufacture the listed controlled substances to produce forensic and research of analytical reference standards for distribution to its customers. In reference to Marihuana (7360) and Tetrahydrocannabinols (7370) the company will manufacture as synthetics only. No other activities for these drug codes are authorized for this registration.

**William T. McDermott,**

*Assistant Administrator.*

[FR Doc. 2020-19805 Filed 9-4-20; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA-707]

#### Importer of Controlled Substances Application: Aspen API, Inc.

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Aspen API, Inc. has applied to be registered as an importer of basic class(es) of controlled substance. Refer to Supplemental Information listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before October 8, 2020. Such persons may also file a written request for a hearing on the application on or before October 8, 2020.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on August 3, 2020, Aspen API, Inc., 2136 South Wolf Road, Des Plaines, Illinois 60018-1932, applied to be registered as an importer of the

following basic class(es) of controlled substance:

Controlled substance	Drug code	Schedule
Remifentanil .....	9739	II

The company plans to import the listed controlled substance as a bulk active pharmaceutical ingredient for distribution to manufacturers of finished dosage prescription drugs. No other activity to this drug code is authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

**William T. McDermott,**

*Assistant Administrator.*

[FR Doc. 2020-19804 Filed 9-4-20; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF JUSTICE

### Notice of Lodging of Proposed Consent Decree Under the Clean Air Act

On August 31, 2020, the U. S. Department of Justice (DOJ) lodged a proposed Consent Decree with the United States District Court for the Southern District of Indiana in *United States and State of Indiana v. Indianapolis Power & Light Company*, Civil Action No. 3:20-cv-202. The lodging of the proposed Decree immediately followed DOJ's filing in the same court of a civil complaint (Complaint) against Indianapolis Power & Light Company (IPL).

The proposed Consent Decree resolves Clean Air Act and related State law claims in the Complaint by the United States on behalf of the U.S. Environmental Protection Agency, and the State of Indiana, by the authority of the Attorney General of Indiana, acting at the request of the Indiana Department of Environmental Management. Under the proposed Decree, IPL agrees, among other things, to undertake measures to reduce pollutant emissions and improve its environmental compliance at the Petersburg Generating Station (Facility) in Pike County, Indiana. In addition, IPL will pay a civil penalty, perform a mitigation project proposing a new, non-emitting source of power to serve the Facility's internal load, and conduct

a State-only Environmentally Beneficial Project.

The publication of this notice opens a period for public comment on the proposed Consent Decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and should refer to *United States and State of Indiana v. Indianapolis Power & Light Company*, D.J. Ref. No. 90-5-2-1-09897/1. All comments must be submitted no later than thirty (30) days after the publication date of this notice. Comments may be submitted either by email or by mail:

To submit comments:	Send them to:
By email .....	<i>pubcomment-ees.enrd@usdoj.gov.</i>
By mail .....	Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, D.C. 20044-7611.

During the public comment period, the proposed Consent Decree may be examined and downloaded at this Justice Department website: <http://www.justice.gov/enrd/consent-decrees>.

We will provide a paper copy of the proposed Consent Decree upon written request and payment of reproduction costs. Please mail your request and payment to: Consent Decree Library, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044-7611.

Please enclose a check or money order for \$19.00 (25 cents per page reproduction cost), payable to the United States Treasury.

**Jeffrey Sands,**

*Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division.*

[FR Doc. 2020-19691 Filed 9-4-20; 8:45 am]

**BILLING CODE 4410-15-P**

## DEPARTMENT OF LABOR

### Veterans' Employment and Training Service

#### Advisory Committee on Veterans' Employment, Training and Employer Outreach (ACVETEO): Meeting

**AGENCY:** Veterans' Employment and Training Service (VETS), Department of Labor (DOL).

**ACTION:** Notice of virtual open meeting.

**SUMMARY:** This notice sets forth the schedule and proposed agenda of a forthcoming meeting of the ACVETEO. The ACVETEO will discuss the DOL core programs and services that assist